Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
VESTLANDETS INNOVASJONSSELSKAP AS currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units, showing a decentralized prosecution landscape. The presence of 3 distinct art units suggests that the institution's research covers several different technical classifications within the biotechnology and pharmaceutical fields. Each of the 3 distinct art units presents a unique set of examination standards, requiring a tailored approach for each of the three pending matters currently under review.
BERRY, LAYLA D is the busiest examiner for the portfolio, currently managing 1 pending office action. With 3 pending office actions in total and 3 distinct examiners involved, the workload is split evenly, with no single examiner handling multiple cases. This distribution requires the institution to manage three separate prosecution tracks, each subject to the specific nuances of a different art unit and examiner. The current workload is light, but the diversity of 3 distinct examiners suggests a need for versatile legal arguments across the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| BAEK, JONGHWAN NMN | 1 | 50.0% | +0.0% |
| CHRISTIANSON, SKYLAR LINDSEY | 1 | 60.9% | +25.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18054504 | SELECTIVE PERFUSION DEVICE AND METHOD | CHRISTIANSON, SKYLAR LINDSEY | 21d |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1618 | 1 |
| 3792 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573963 | NAD-AUGMENTATION THERAPY FOR PARKINSON'S DISEASE | BERRY, LAYLA D | 1693 | §102§103§112DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18255557 | IMAGING METHODS AND RADIOTRACERS FOR USE THEREIN | BAEK, JONGHWAN NMN | 1618 | §103 | Final Rejection | 15d overdue | Pending | Jun 01, 2023 |
| 18054504 | SELECTIVE PERFUSION DEVICE AND METHOD | CHRISTIANSON, SKYLAR LINDSEY | 3792 | §103 | Final Rejection | 21d | Pending | Nov 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVESTLANDETS INNOVASJONSSELSKAP AS has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Layla D Berry has the most, with 1 of VESTLANDETS INNOVASJONSSELSKAP AS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
